Though erythrocytosis is not a major side effect reported with aromatase inhibitor use, aromatase inhibitors prevent peripheral conversion of testosterone to estradiol (and androstenedione to estrone), leading to increased levels of testosterone, which would explain the erythrocytosis seen in our case. This evidence concerns the gene CYP19A1 and polycythemia.